Post by Admin/ Traveler on Dec 18, 2017 18:53:02 GMT
Or at least some of the political issues with testing regarding Lyme disease.
Just a couple of teasers from the article:
"Recently, a group of Lyme disease patients in the United States filed a lawsuit against several major health insurance companies and a group of Lyme disease specialists seeking treble damages for RICO Act (Racketeer Influenced and Corrupt Organizations Act) and Sherman Act antitrust violations. Four months earlier, Dr. Sin Hang Lee also initiated a legal action against the CDC for anti-competitive campaign to stifle the use and availability of his DNA-based direct test to diagnose Lyme disease. More recently, court materials surfaced which show credible reasons to believe that the role of Yale University in suppressing development and use of direct detection methods in the diagnosis of Lyme disease at the early stage of infection for patient care should also be scrutinized by the media and the lawyers of the RICO suit.
“The medical profession has been transformed into a “healthcare industry”. In this world of free market economy, the healthcare providers in the pain management business may arguably have the rights to create public need for their services, just like Apple creating demand for its iPhone.” Dr. Lee"
---------------------------------------------------------------------
"Can you specify the kinds of resistance you have encountered?
Dr. Lee: Except for the first technical paper, all my manuscripts based on studies of Lyme patient materials were rejected by mainstream American medical journals, including the American Journal of Clinical Pathology, the Journal of Clinical Microbiology and the Clinical Chemistry.
The reasons for rejection alleged ‘lack of readership interest at the editorial screening stage’, or a low priority score. This was quite a ‘coincidental’ message to come from all these journals and it meant the manuscripts were rejected by editorial censorship and had to be published in foreign journals.
Although I had never met him in person, I knew Dr. Allen Steere was a pioneer in Lyme disease starting in Connecticut. Therefore, after my first technical paper on Lyme disease was accepted for publication in 2009, I sent the accepted manuscript to Dr. Steere at the Massachusetts General Hospital and informed him that there is an emerging reliable DNA method for diagnosis of early Lyme infection.
To my surprise, Steere wrote back in an email that he had no interest in reading the manuscript, because he was working on the C6 Lyme antibody test."
---------------------------------------------
"Q. I have obtained a copy of the formal complaint your lawyer filed on your behalf with the Superior Court in Connecticut. In this document, you state that Yale had you fired because their serology-based Lyme diagnostic tests could not compete with your nested PCR/DNA sequencing test to diagnose Lyme disease at early stage of infection. As I understand your complaint, a Yale medical group doctor became the new chairperson at Milford Hospital and then told the human resources director to fire you. Can you confirm if I have read the document correctly?
Dr. Lee: Yes. Your summary is correct. It is common knowledge that the Yale medical group has focused on serology-based tests in order to diagnose Lyme disease at convalescent stage of the infection and I want to diagnose Lyme disease at the early stage of infection before Lyme antibodies become measurable."
Should the Lyme Patients’ RICO lawsuit include Yale?
Just a couple of teasers from the article:
"Recently, a group of Lyme disease patients in the United States filed a lawsuit against several major health insurance companies and a group of Lyme disease specialists seeking treble damages for RICO Act (Racketeer Influenced and Corrupt Organizations Act) and Sherman Act antitrust violations. Four months earlier, Dr. Sin Hang Lee also initiated a legal action against the CDC for anti-competitive campaign to stifle the use and availability of his DNA-based direct test to diagnose Lyme disease. More recently, court materials surfaced which show credible reasons to believe that the role of Yale University in suppressing development and use of direct detection methods in the diagnosis of Lyme disease at the early stage of infection for patient care should also be scrutinized by the media and the lawyers of the RICO suit.
“The medical profession has been transformed into a “healthcare industry”. In this world of free market economy, the healthcare providers in the pain management business may arguably have the rights to create public need for their services, just like Apple creating demand for its iPhone.” Dr. Lee"
---------------------------------------------------------------------
"Can you specify the kinds of resistance you have encountered?
Dr. Lee: Except for the first technical paper, all my manuscripts based on studies of Lyme patient materials were rejected by mainstream American medical journals, including the American Journal of Clinical Pathology, the Journal of Clinical Microbiology and the Clinical Chemistry.
The reasons for rejection alleged ‘lack of readership interest at the editorial screening stage’, or a low priority score. This was quite a ‘coincidental’ message to come from all these journals and it meant the manuscripts were rejected by editorial censorship and had to be published in foreign journals.
Although I had never met him in person, I knew Dr. Allen Steere was a pioneer in Lyme disease starting in Connecticut. Therefore, after my first technical paper on Lyme disease was accepted for publication in 2009, I sent the accepted manuscript to Dr. Steere at the Massachusetts General Hospital and informed him that there is an emerging reliable DNA method for diagnosis of early Lyme infection.
To my surprise, Steere wrote back in an email that he had no interest in reading the manuscript, because he was working on the C6 Lyme antibody test."
---------------------------------------------
"Q. I have obtained a copy of the formal complaint your lawyer filed on your behalf with the Superior Court in Connecticut. In this document, you state that Yale had you fired because their serology-based Lyme diagnostic tests could not compete with your nested PCR/DNA sequencing test to diagnose Lyme disease at early stage of infection. As I understand your complaint, a Yale medical group doctor became the new chairperson at Milford Hospital and then told the human resources director to fire you. Can you confirm if I have read the document correctly?
Dr. Lee: Yes. Your summary is correct. It is common knowledge that the Yale medical group has focused on serology-based tests in order to diagnose Lyme disease at convalescent stage of the infection and I want to diagnose Lyme disease at the early stage of infection before Lyme antibodies become measurable."
Should the Lyme Patients’ RICO lawsuit include Yale?